Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
Study Details
Study Description
Brief Summary
To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Objectives:
-
To estimate the prevalence and severity of adverse and functional outcomes in survivors of benign and malignant paranasal sinus, nasopharynx and skull base tumors.
-
To estimate the prevalence of health promotion behaviors during skull base tumor survivorship
-
To identify possible mediators or predictors of survivorship outcomes and health behaviors in survivors of skull base tumors.
-
To develop a database of demographic, clinicopathologic, recurrence, survival, functional and patient reported outcomes (PROS) for patients with benign and malignant paranasal sinus, nasopharyngeal and skull base tumors.
-
To assess the utility and limitations of PROs in evaluating functional impairments and symptom burden in skull base patients.
Study Design
Outcome Measures
Primary Outcome Measures
- MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN) [through study completion; an average of 1 year]
MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN) is a disease specific PRO instrument validated for patients with head and neck cancer. It is the most commonly utilized instrument in the head and neck cancer population, of which sinonasal and nasopharyngeal tumors are disease subsites. Score scale from 0 (symptom has been present) to 10 (the symptom was as bad as you can imagine it could be)
Eligibility Criteria
Criteria
Inclusion criteria:
-
Previously untreated patients with or suspected to have sinonasal malignancy or nasopharyngeal malignancy diagnosis based on either outside pathology report or MD Anderson pathology report.
-
Age ≥ 18 years
-
Plan to obtain the majority of treatment at MDACC including surgery and radiotherapy
-
Ability to understand and willingness to sign written informed consent
Exclusion criteria:
-
History of the previous solid or liquid malignancies, apart from skin cancers treated with local therapy.
-
Existing neurocognitive impairment that is not the result of sinonasal and nasopharyngeal cancers or is treatment.
-
Previous treatment for sinonasal or nasopharyngeal carcinomas, apart from biopsy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | M D Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
Investigators
- Principal Investigator: Shirley Su, MBBS, M.D. Anderson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- PA18-0969
- NCI-2023-01436